The company reported a 21.7 per cent decline in net profit at Rs 6.11 billion for the quarter ended September 2018, owing to rise in costs.
Aurobindo Pharma’s net profit was Rs611 crore in the quarter ended 30 September, compared with Rs781 crore a year earlier
Nov 12 (Reuters) - Aurobindo Pharma Ltd ARBN.NS , India's second-largest drugmaker by market capitalisation, posted a 21.7 percent fall in its second-quarter profit on Monday,...
In last few days, we all have seen a good amount of volatility in our markets. It is common to see when Dollor currency has reached its all time highs. In other words, when Rupee...
When I think of how the key Indian indexes performed this week then only one word comes to my mind which is ‘Nifty Sensex tu hai insane’. Overall, the key Indian...
Today I shall be analyzing Ramco Cements and Aurobindo Pharma (NS:ARBN) as I believe there is currently a lot of potential in these two stocks. Both the stocks are providing...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Sell||Buy||Buy|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||BUY||Strong Buy|
|Summary||Strong Sell||Strong Sell||Strong Sell||Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Black Crows||1D||Current|
|Engulfing Bearish||1D||2||Nov 12, 2018|
|Falling Three Methods||30||2||Nov 14, 2018 11:00|
|Three Black Crows||5H||3||Nov 13, 2018 08:30|
|Tata Steel Ltd||598.60||610.60||593.05||+9.40||+1.60%||15.16M||12:25:19|
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.Read More
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.